Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.
A three-way race is on to determine which Car-T therapy Gilead will take into pivotal trials.
Two anti-TROP2 ADCs join cell therapies and Teva’s anti-PD-1 in first-in-human studies.
After being burned by Point, Lilly is taking a slower approach with Radionetics.
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.